J&J, Bayer Cleared of Responsibility in Third Xarelto Trial

Aug. 21, 2017, 9:14 PM

Johnson & Johnson and Bayer AG didn’t defectively design Xarelto blood thinner, federal jury in Mississippi ruled Aug. 18. (Mingo v. Janssen Research and Development LLC, E.D. La., 15-cv-3469, 8/18/17) (In RE Xarelto Products Liability Litigations, E.D. La., 14-MD-2592, 8/18/17).

Mississippi grandmother, Dora Mingo, had accused the companies of misleading her doctors about the. drug’s health risks.

The verdict is the companies’ third-straight win in cases over Xarelto, which is developed jointly by J&J’s unit Janssen and Bayer.

“The jury’s decision reflects the facts of this case and the appropriateness of Xarelto,” said Janssen’s Sarah Freeman....

To read the full article log in. To learn more about a subscription click here.